Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 2, 2009, Pages 81-89

  Fukasawa, Akiko ^a   Aoyama, Takahiko ^a   Nagashima, Takashi ^a   Fukuda, Noboru ^a   Ueno, Takahiro ^b   Sugiyama, Hiroshi ^c   Nagase, Hiroki ^a,b   Matsumoto, Yoshiaki ^a  

^a NIHON UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Catenary two compartment model; Intravenous administration; Pharmacokinetics; Pyrrole imidazole polyamides

Indexed keywords

ACETYL IMIDAZOLEPYRROLEPYRROLE IMIDAZOLEPYRROLEPYRROLE BETA ALANINE N,N DIMETHYLAMINOPROPYLAMIDE; ACETYL PYRROLEIMIDAZOLE BETA IMIDAZOLEIMIDAZOLE PYRROLEPYRROLE BETA PYRROLEPYRROLE BETA ALANINE N,N DIMETHYLAMINOPROPYLAMIDE; ACETYL PYRROLEPYRROLE BETA PYRROLEIMIDAZOLEPYRROLE PYRROLEPYRROLEPYRROLE BETA IMIDAZOLEPYRROLE BETA ALANINE N,N DIMETHYLAMINOPROPYLAMIDE; POLYAMIDE; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; NYLON; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; NONHUMAN; RAT; STEADY STATE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LUNG; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TIME; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; INJECTIONS, INTRAVENOUS; LUNG; MALE; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; NYLONS; PYRROLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; RATS, WISTAR; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 63049103416     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.648     Document Type: Article

References (29)

1. Trauger JW, Baird EE, Dervan PB. Recognition of DNA by designed ligands at subnanomolar concentrations. Nature 1996; 382: 559-561.
2. Tao ZF, Fujiwara T, Saito I, Sugiyama H. Sequence-specific DNA alkylation by hybrid molecules between segment A of duocarmycin A and pyrrole/imidazole diamide. Angew Chem Int Ed 1999; 38: 650-653.
3. Pilch DS, Poklar N, Gelfand CA, et al. Binding of a hairpin polyamide in the minor groove of DNA: sequence-specific enthalpic discrimination. Proc Natl Acad Sci USA 1996; 93: 8306-8311.
4. White S, Baird EE, Dervan PB. On the pairing rules for recognition in the minor groove of DNA by pyrrole-imidazole polyamides. Chem Biol 1997; 4: 569-578.
5. Murty MS, Sugiyama H. Biology of N-methylpyrrole-N-methylimidazole hairpin polyamide. Biol Pharm Bull 2004; 27: 468-474.
6. Dickinson LA, Gulizia RJ, Trauger JW, et al. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc Natl Acad Sci USA 1998; 95: 12890-12895.
7. Matsuda H, Fukuda N, Ueno T, et al. Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-β1 promoter for treatment of progressive renal diseases. J Am Soc Nephrol 2006; 17: 422-432.
8. Chou CJ, Farkas ME, Tsai SM, Alvarez D, Dervan PB, Gottesfeld JM. Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia. Mol Cancer Ther 2008; 7: 769-778.
9. Fukasawa A, Nagashima T, Aoyama T, et al. Optimization and validation of a high-performance liquid chromatographic method with UV detection for the determination of pyrrole-imidazole polyamides in rat plasma. J Chromatogr B 2007; 859: 272-275.
10. Wieser ME. Atomic weights of the elements 2005. Pure Appl Chem 2006; 78: 2051-2066.
11. Brown PH, Krishnamurthy GT, Bobba VV, Kingston E. Radiation dose calculation for Tc-99m HIDA in health and disease. J Nucl Med 1981; 22: 177-183.
12. Hazra A, Pyszczynski N, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Biopharm Drug Dispos 2007; 28: 263-273.
13. Dutta S, Matsumoto Y, Gothgen NU, Ebling WF. Concentration-EEG effect relationship of propofol in rats. J Pharm Sci 1997; 86: 37-43.
14. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource: LA, 1997.
15. Beal SL, Sheiner LS. NONMEM User's Guide. NONMEM Project Group, University of California at San Francisco: San Francisco, 1994.
16. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/Pharmacokinetics UK joint working party. Drug Inf J 1995; 29: 1039-1048.
17. McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 2008; 48: 19-25.
18. Da Ros L, Squassante L, Milleri S. Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. Clin Pharmacokinet 2003; 42: 99-106.
19. Suzawa T, Nagamura S, Saito H, Ohta S, Hanai N, Yamasaki M. Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly(ethylene glycol) and dipeptide for the development of immunoconjugate. J Control Release 2000; 69: 27-41.
20. Lockhart AC, HowardM, Hande KR, et al. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 2004; 10: 468-475.
21. Shinohara K, Narita A, Oyoshi T, Bando T, Teraoka H, Sugiyama H. Sequence-specific gene silencing in mammalian cells by alkylating pyrrole-imidazole polyamides. J Am Chem Soc 2004; 126: 5113-5118.
22. Shinohara K, Bando T, Sasaki S, Sakakibara Y, Minoshima M, Sugiyama H. Antitumor activity of sequence-specific alkylating agents: pyrolle-imidazole CBI conjugates with indole linker. Cancer Sci 2006; 97: 219-225.
23. Dickinson LA, Burnett R, Melander C, Edelson BS, Arora PS, Dervan PB. Arresting cancer proliferation by small-molecule gene regulation. Chem Biol 2004; 11: 1589-1594.
24. Mager DE, Jusko WJ. Quantitative structure--pharmacokinetic/ pharmacodynamic relationships of corticosteroids in man. J Pharm Sci 2000; 91: 2441-2451.
25. Alberts SR, Erlichman C, Reid JM, et al. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin Cancer Res 1998; 4: 2111-2117.
26. Wester RC, Noonan PK, Smeach S, Kosobud L. Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. J Pharm Sci 1983; 72: 745-747.
27. Rodgers T, Leahy D, Rowland M. Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst β-blocking drugs in rat. J Pharm Sci 2005; 94: 1237-1248.
28. Macintyre A, Cutler D. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos 1988; 9: 513-526.
29. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27: 766-777.